{"id":"W4387134990","doi":"10.1136/ijgc-2023-esgo.13","title":"#267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada); McGill University Health Centre","funders":"National Cancer Institute; Daiichi Sankyo Europe; MSD Italia; Genentech; National Institutes of Health; PharmaMar; Eisai; Seagen; Silverback Therapeutics; Puma Biotechnology; Deciphera Pharmaceuticals; Clovis Oncology; Novocure; Amgen; Relay Therapeutics; Mersana Therapeutics; Karyopharm Therapeutics; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Carboplatin; Toxicity; Endometrial cancer; Internal medicine; Population; Paclitaxel; Placebo; Cancer; Adverse effect; Gastroenterology; Oncology; Surgery; Chemotherapy; Urology; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001996235,0.000749198,0.001967716,0.0002045855,0.000245659,0.001178421,0.0003761885,0.0006594298,0.006115578],"category_scores_gemma":[0.001627224,0.0002545514,0.005938766,0.0003476243,0.0004546918,0.0006710933,0.0003003316,0.002025994,0.0005109485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007241333,"about_ca_system_score_gemma":0.0007389621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002260804,"about_ca_topic_score_gemma":0.005105742,"domain_scores_codex":[0.9993451,0.0003955306,0.00005139842,0.00008853942,0.00003909328,0.00008037578],"domain_scores_gemma":[0.9992957,0.0002534914,0.0001706016,0.00004752435,0.00005363376,0.0001790756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9407703,0.0007347041,0.009211472,0.002061021,0.01606328,0.00007450889,0.00003562706,0.001354144,0.001393015,0.0003187511,0.004990559,0.02299258],"study_design_scores_gemma":[0.8384991,0.05796456,0.06697989,0.0004060338,0.02456334,0.000144942,0.00009027767,0.003151235,0.0006584652,0.001162463,0.006306787,0.00007304086],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9420103,0.03569922,0.0009402721,0.003733886,0.002167415,0.0008418101,0.007623355,0.00009676824,0.006886949],"genre_scores_gemma":[0.9845002,0.004409562,0.0006042679,0.001542548,0.0008003009,0.0004216229,0.004012776,0.00002878788,0.003680011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006115578,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05397103087149974,"score_gpt":0.361832289369025,"score_spread":0.3078612584975253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}